StemCell Therapy

HAMILTON, BERMUDA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA, Jan. 24, 2024 -- Altamira Therapeutics Ltd. (Nasdaq: CYTO) ("Altamira" or the "Company"), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has filed a second provisional patent application with the United States Patent and Trade Office (USPTO) to provide broad coverage of different KRAS mutations in human cancer treatment with nanoparticles comprising the Company’s OligoPhore™ platform and a single siRNA sequence, polyKRASmut. The nanoparticles are developed by Altamira as AM-401.

See the rest here:
Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment

Subject enrollment is expected in Q1 2024 Subject enrollment is expected in Q1 2024

View original post here:
AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization for Phase 2 Study of Ampligen® for the Treatment of Locally Advanced...

-Project NextGen Collaboration will Support Capricor’s StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic-

Original post:
Capricor Therapeutics Announces Collaboration with the National Institutes of Health for Clinical Trial of Novel Exosome-Based Multivalent Vaccine...

New ticker symbol goes into effect immediately New ticker symbol goes into effect immediately   

Read more here:
PharmAla receives new “MDXXF” ticker from FINRA for OTCQB Listing

Seasoned leader in drug discovery and development Seasoned leader in drug discovery and development

Read more:
OrphAI Therapeutics Announces Appointment of Jay Fine to Board of Directors

VANCOUVER, British Columbia, Jan. 24, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF), please note that in the 8th paragraph of the letter, the company plans to launch its first product early in the 1st quarter of 2025, not the 1st quarter of 2024 as previously stated. The corrected release follows:

See the article here:
CORRECTION -- Sirona Biochem Corporate Update January 2024

Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM) Regeneron Science Talent Search Showcases Exceptional Young Leaders with Innovative Ideas in Science, Technology, Engineering and Math (STEM)

Here is the original post:
Top 40 High School Scientists in Prestigious Regeneron Science Talent Search to Compete for $1.8 Million in Awards

SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial results for the fiscal year 2024 (FY2024) third quarter after the market closes on Wednesday, February 7, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter’s financial results and report on business progress.

Visit link:
23andMe to Report FY2024 Third Quarter Financial Results

FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that the independent members of its Board of Directors approved equity awards under Ocuphire’s 2021 Inducement Plan, as a material inducement to two new employees in connection with their employment with the Company effective on January 18, 2024. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

Read the original here:
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (“NASH”) and other diseases with significant unmet medical needs, today announced the half-year report of its liquidity contract with Kepler Cheuvreux.Under the liquidity contract granted to Kepler Cheuvreux by Inventiva, the following resources were available in the liquidity account as of December 31, 2023:

Excerpt from:
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux

NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN

Visit link:
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device. REBUILD met the criteria set by the FDA for Breakthrough Devices, potentially providing a novel treatment of an often irreversibly debilitating condition: incisional hernia. Less than 7% of Breakthrough Devices are in the field of general surgery, making REBUILD a standout product in a sector of medicine struggling to make profound advances.

See the rest here:
AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device

PRESS RELEASE

Go here to read the rest:
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress

Continue reading here:
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights

TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid cells to activate anti-tumor immunity in hematological and solid tumor microenvironments, today provided details from its further analysis of data from the completed Phase 1 part of the ongoing BEXMAB trial.

More:
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population

USES AND APPLICATIONS OF BIOTECHNOLOGY

Biotechnological innovations are already part of our daily lives and we find them in pharmacies and supermarkets, among many other places. In addition, they were of key importance during the fight against the COVID-19 pandemic as they helped decipher the genome of the virus and in understanding how our body's defence mechanism works against infectious agents.

Biotechnology will therefore play a crucial role in the society of the future in preventing and containing potential pathogens. But this is just one of its many applications... Below, we review some of the most relevant in different fields:

The development of insulin, the growth hormone, molecular identity and diagnostics, gene therapies and vaccines such as hepatitis B are some of the milestones of biotechnology and its alliance with genetic engineering. In addition, it is also used in the diagnosis of diseases due to its ability to perform very complicated tests in a shorter time and at lower cost.

The revolution of the new smart materials hand-in-hand with biotechnology has only just begun, with the main advantage that it can make easily degradable products. Such products help the environment because they generate less waste at the time of destruction, as is the case with biodegradable plastics.

In addition to the genetically modified foods mentioned above, thanks to biotechnology products such as WEMA have been created, a type of crop resistant to droughts and certain insects that may prove essential in fighting hunger in Africa.

Through bioremediation processes, very useful for ecological recovery, the catabolic properties of microorganisms, fungi, plants and enzymes are used to restore contaminated ecosystems.

Read more from the original source:
What is Biotechnology? Types and Applications - Iberdrola

Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week?  InvestorsObserver

Read more here:
Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver

Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday?  InvestorsObserver

See the article here:
Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver

Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week?  InvestorsObserver

The rest is here:
Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver

Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week?  InvestorsObserver

Follow this link:
Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver